Recent News

• 04.24.2025 - Travere Therapeutics to Report First Quarter 2025 Financial Results
• 04.11.2025 - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.31.2025 - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
• 03.17.2025 - Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
• 03.17.2025 - Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
• 03.17.2025 - Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
• 03.12.2025 - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.12.2025 - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.12.2025 - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.11.2025 - Leerink Partners Global Biopharma Conference

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.11.2025 - 144 Report of proposed sale of securities
• 04.01.2025 - ARS Annual Report to Security Holders
• 04.01.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.01.2025 - DEF 14A Other definitive proxy statements
• 03.17.2025 - 8-K Current report